c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

Gullick, William J.; Love, Sharon; Wright, Chris; Barnes, David J.; Gusterson, Barry A.; Harris, Adrian L.; Altman, D G

doi:10.1038/bjc.1991.100

Cited by 307 publications

(126 citation statements)

References 24 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Ovet-expression of c-erbB-2 protein, on the other hand, was strongly correlated with DFS and S in our patients. Although some earlier studies have failed to show an association between prognosis and overexpression of the c-erbB-2 protein detected by IHC (14,15,20), there is a gencral agreement among more recently published reports that overexpression of the c-erbB-2 gene product is related to poor survival in breast cancer (10)(11)(12)(13)(33)(34)(35)(36). Our results are consistent with this emerging consensus.…”

Section: Discussionsupporting

confidence: 82%

Prognostic Association of C-Erbb-2 Oncogene Amplification and Protein Overexpression in Human Breast Cancer Using Archival Tissues a Comparative Study

et al. 1994

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

Prognostic Association of C-Erbb-2 Oncogene Amplification and Protein Overexpression in Human Breast Cancer Using Archival Tissues a Comparative Study

et al. 1994

View full text Add to dashboard Cite

“…Assessment of the copy number of the Her-2neu gene and its expression has evolved as an important prognostic indicator in breast, ovarian, and uterine cancers. [35][36][37][38][39] The characteristic rearrangement of RARA with the PML (promyelocytic leukemia) gene on 15q22 has proven to be integral in the diagnosis and treatment of acute promyelocytic leukemia. [40][41][42] Since the cytogenetic findings of the current study and a review of the literature indicated that the 17p11-13 region likely harbors an oncogene of etiologic importance in aneurysmal bone cyst, efforts to further characterize the critically involved 17p breakpoint were conducted.…”

Section: Discussionmentioning

confidence: 99%

Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: aberrations of 17p mapped to 17p13.2 by fluorescence in situ hybridization

et al. 2004

View full text Add to dashboard Cite

Aneurysmal bone cyst is a benign, cystic lesion of bone composed of blood-filled spaces separated by fibrous septa. Relatively few cases of aneurysmal bone cyst have been cytogenetically characterized, yet abnormalities of the short arm of chromosome 17 appear to be recurrent. In this study, conventional cytogenetic analysis of 43 aneurysmal bone cyst specimens from 38 patients over a 12-year period revealed clonal chromosomal abnormalities in 12 specimens. Karyotypic anomalies of 17p, including a complex translocation and inversion, were identified in eight of these 12 specimens. In an effort to further define the aberrant 17p breakpoint, fluorescence in situ hybridization (FISH) analyses were performed using a series of probe combinations spanning a 5.1 Mb region between the TP53 (17p13.1) and Miller-Dieker lissencephaly syndrome (17p13.3) gene loci. These studies revealed the critical breakpoint locus at 17p13.2, flanked proximally by an RP11-46I8, RP11-333E1, and RP11-457I18 bacterial artificial chromosome (BAC) probe cocktail and distally by an RP11-198F11 and RP11-115H24 BAC and RP5-1050D4 P1 artificial chromosome (PAC) probe cocktail. Overall, abnormalities of the 17p13.2 locus were identified by metaphase and/or interphase cell FISH analysis in 22 of 35 (63%) aneurysmal bone cyst specimens examined including 26 karyotypically normal specimens. These cytogenetic and molecular cytogenetic findings expand our knowledge of chromosomal alterations in aneurysmal bone cyst, further localize the critically involved 17p breakpoint, and provide an alternative approach (ie FISH) for detecting 17p abnormalities in nondividing cells of aneurysmal bone cysts. The latter could potentially be utilized as an adjunct in diagnostically challenging cases.

show abstract

“…Both in situ and invasive low-grade lesions express oestrogen and progesterone receptors, but are usually negative for oncoproteins (HER/neu and p53). High-grade lesions exhibit the reverse (Hitchcock et al, 1989;Gullick et al, 1991;Barnes et al, 1993;Millis et al, 1996;Ellis et al, 1999). Molecular genetic studies find that low-grade lesions often demonstrate 16q deletions, while high-grade lesions have allelic losses of more chromosomal areas frequently including 1p, 1q, 6q, 9p, 11p, 13q and 17q.…”

Section: Discussionmentioning

confidence: 99%

Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast

et al. 2004

View full text Add to dashboard Cite

The grade of recurrent in situ and invasive carcinoma occurring after treatment of pure ductal carcinoma in situ (DCIS) has been compared with the grade of the original DCIS in 122 patients from four different centres (The Royal Marsden Hospitals, London and Sutton, 57 patients; Guy's Hospital, London, 19 patients; Nottingham City Hospital, 31 patients and The Royal Liverpool Hospital, 15 patients). The recurrent carcinoma was pure DCIS in 70 women (57%) and in 52 women (43%) invasive carcinoma was present, which was associated with an in situ element in 43. In all, 19 patients developed a second recurrence (pure DCIS in 11 and invasive with or without an in situ element in eight). The majority of invasive carcinomas followed high-grade DCIS. There was strong agreement between the grade of the original DCIS and that of the recurrent DCIS (k ¼ 0.679), which was the same in 95 of 113 patients (84%). The grade of the original DCIS showed only fair agreement with the grade of recurrent invasive carcinoma (k ¼ 0.241), although agreement was stronger with the pleomorphism score of the recurrent carcinoma (k ¼ 0.396). There was moderate agreement, in recurrent invasive lesions, between the grade of the DCIS and that of the associated invasive element (k ¼ 0.515). Other features that showed moderate or strong agreement between the original and recurrent DCIS were necrosis and periductal inflammation. The similarity between the histological findings of the original and subsequent DCIS is consistent with the concept that recurrent lesions represent regrowth of residual carcinoma. In addition, although agreement between the grade of the original DCIS and that of any subsequent invasive carcinoma was only fair, there is no suggestion that low-grade DCIS lesions progress to higher grade lesions or to the development of higher grade invasive carcinoma. This is in agreement with immunohistochemical and molecular data indicating that low-grade and high-grade mammary carcinomas are quite different lesions.

show abstract

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

Cited by 307 publications

References 24 publications

Prognostic Association of C-Erbb-2 Oncogene Amplification and Protein Overexpression in Human Breast Cancer Using Archival Tissues a Comparative Study

Prognostic Association of C-Erbb-2 Oncogene Amplification and Protein Overexpression in Human Breast Cancer Using Archival Tissues a Comparative Study

Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: aberrations of 17p mapped to 17p13.2 by fluorescence in situ hybridization

Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast

Contact Info

Product

Resources

About